Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 2
Submit an article Journal homepage
155
Views
56
CrossRef citations to date
0
Altmetric
Review

Agents and strategies in development for improved management of herpes simplex virus infection and disease

Gerald Kleymann Leopoldshöherstraße 7, D-32107 Bad-Salzuflen, Germany. [email protected]
Pages 135-161 | Published online: 22 Apr 2005

Bibliography

  • KNIPE DM, HOWLEY PM: Fields (4th Edition). Lippincott Williams& Wilkins, Philadelphia PA, USA (2001).
  • •The reference book.
  • MALKIN JE: Epidemiology of genital herpes simplex virus infection in developed countries. Herpes (2004) 11 (Suppl. 1):2A–23A.
  • WEISS H: Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes (2004) 11 (Suppl. 1):24A–35A.
  • PEBODY RG, ANDREWS N, BROWN D et al.: The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sex. Transin. Infect. (2004) 80(3):185–191.
  • LEONE P, FLEMING DT, AW, LI L, JUSTUS S: Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. Sex. Transin. Dis. (2004) 31(5):311–316.
  • SOLOMON L, CANNON MJ, M, GRABER JM, NT, REEVES WC: Task Force on Herpes Simplex Virus Resistance. Epidemiology of recurrent genital herpes simplex virus types 1 and 2. Sex. Transin. Infect. (2003) 79(6):456–459.
  • SMITH JS, ROBINSON NJ: Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. ./. Infect. Dis. (2002) 186\(Suppl. 1):S3–S28.
  • SPEAR PG: Herpes simplex virus: receptors and ligands for viral entry. Cell Microbiol (2004) 6(5):401–410.
  • SACKS SL, GRIFFITHS PD, COREY L et al.: HSV shedding. Antiviral Res. (2004) 63\(Suppl. 1):519–526.
  • USTACELEBI S: Diagnosis of herpes simplex virus infections. ./. Clin. Virol (2001) 21(3):255–259.
  • STRICK L, WALD A: Type-specific testing for herpes simplex virus. Expert Rev Mol. Diagn. (2004) 4(4):443–53.
  • LANGENBERG A: Interrupting herpes simplex virus type 2 transmission: the role of condoms and microbicides. Herpes (2004) (Suppl. 3):147A–54A.
  • ZEITLIN L, WHALEY KJ: Microbicides for preventing transmission of genital herpes. Herpes (2002) 9(1):4–9.
  • •A thorough review of microbicides.
  • STANBERRY LR: Clinical trials of and therapeutic herpes simplex virus vaccines. Herpes (2004) 11 (Suppl. 3):161A–169A.
  • •Discussing the objectives of vaccines against herpes.
  • STRAUS SE, WALD A, KOST RG et al: Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. I. Infect. Dis. (1997) 176(5):1129–1134.
  • STRAUS SE, COREY L, BURKE RL et al.: Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet (1994) 343(8911):1460–1463.
  • VANDEPAPELIERE P: Therapeutic vaccination against chronic viral infections. Lancet Infect Dis. (2002) 2(6):353–367.
  • JONES CA, CUNNINGHAM AL: Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Herpes (2004) 11(1):12–17.
  • TOKA FN, PACK CD, ROUSE BT: Molecular adjuvants for mucosal immunity. Iminunol. Rev (2004) 199:100–112.
  • WHITLEY RJ: Herpes simplex vaccines in: New generation vaccines Ord Edition" MM Levine, JB Kaper, R Rappuoli, MA Liu, MF Good (Eds), Marcel Dekker, Inc., New York, NY, USA (2004).
  • STANBERRY LR: Prophylactic vaccines. In: Sexually Transmitted Diseases: Vaccines, Prevention and Control. Lawrence R Stanberry, David I Bernstein (Eds), Academic Press, San Diego, CA, USA (2000).
  • COREY L, LANGENBERG AG, ASHLEY R et al.: Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. "AMA (1999) 282(4):331–40.
  • STANBERRY LR, SPRUANCE SL, CUNNINGHAM AL et al.: Glycoprotein-D-adjuvant vaccine to prevent genital. N Engl. I Med. (2002) 347(21):1652–1661.
  • EO SK, PACK C, KUMARAGURU U, ROUSE BT: Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections. Expert Opin. Biol. Ther. (2001) 1(2):213–225.
  • VAZQUEZ M: Varicella zoster virus infections in children after the introduction of live attenuated varicella vaccine. Curr. Opin. Pediatr. (2004) 16(1):80–84.
  • RENTIER B, GERSHON AA: European Working Group on Varicella. Consensus: varicella vaccination of healthy children - a challenge for Europe. Pediatr. Infect. Dis. I (2004) 23(5):379–389.
  • FAVOREEL HW, NAUWYNCK HJ, PENSAERT MB: Immunological hiding of herpesvirus-infected cells. Arch. Vita (2000) 145(7):1269–1290.
  • KOELLE DM, COREY L: Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev (2003) 16(1):96–113.
  • POLLARA G, KATZ DR, CHAIN BM: The host response to herpes simplex virus infection. Curr. Opin. Infect. Dis. (2004) 17(3):199–203.
  • TRAN H, MORENO G, SHUMACK S: Imiquimod as a dermatological therapy. Expert Opin. Pharinacother. (2004) 5(2):427–438.
  • JURK M, HEIL F, VOLLMER J et al: Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Inununol. (2002) 3(6)499.
  • HEMMI H, KAISHO T, TAKEUCHI 0 et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Inununol. (2002) 3(2):196–200.
  • SAUDER DN, SMITH MH, SENTA-McMILLIAN T, SORIA I, MENG TC: Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antlinicrob. Agents Chemother. (2003) 47(12):3846–3852.
  • JONES T: Resiquimod 3M. Curr. Opin. Investig. Drugs (2003) 4(2):214–218.
  • MASTROLORENZO A, TIRADRITTI L, SALIMBENI L, ZUCCATI G: Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection. Int. STD AIDS (1995) 6:431–435.
  • CARR JA, ROGERSON J, MJ, ROBERTS NA, BOOTH RF: Interleukin-12 exhibits potent antiviral activity in experimental infections.Virol. (1997) 71(10):7799–7803.
  • HUKKANEN V, BROBERG E, SALMI A, ERALINNA JP: Cytokines in experimental herpes simplex virus infection. Int. Rev Iminunol. (2002) 21(4-5):355–371.
  • SYED TA, AHMADPOUR OA, SA, AHMAD SH: Human leukocyte interferon-alpha in a hydrophilic cream versus in a gel for the treatment of genital herpes in males: a placebo-controlled, double-blind, comparative study. J. Dermatol. (1997) 24(9):564–568.
  • VOLLSTEDT S, ARNOLD S, C et al.: Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1. J. Vita (2004) 78(8):3846–3850.
  • KATZE MG, HEY, GALE M JR: Viruses and interferon: a fight for supremacy. Nat. Rev Iminunol. (2002) 2(9):675–87.
  • HARANDI AM:The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges. I Clin. Virol. (20 0 4)30 (3) :207–210 .
  • ULEVITCH RJ: Therapeutics targeting the innate immune system. Nat. Rev Inununol. (2004) 4(7):512–20.
  • KAUFMAN HE: Clinical cure of herpes simplex keratitis by 5-iodo-2'-deoxyuridine. Proc. Soc. Exp. Biol. Med. (1962) 109:251–252.
  • KAUFMAN HE, HEIDELBERGER C: Therapeutic antiviral action of 5-trifluoromethy1-2'-deoxyuridine. Science (1964) 145:585–586.
  • WHITLEY RJ, SOONG SJ, DOLIN R, GALASSO GJ, CHIEN LT, ALFORD CA: Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. New England Med. (1977) 297:289–294.
  • ELION GB, FURMAN PA, FYFE JA, DE MIRANDA P, BEAUCHAMP L, SCHAEFFER HJ: The selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Nati Acad. Li. USA (1977) 74:5716–5720.
  • SCHAEFFER HJ, BEAUCHAMP L, DE MIRANDA P, ELION GB, BAUER DJ, P: 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature (1978) 272(5654):583–585. Landmark paper on antiviral research.
  • O'BRIEN JJ, CAMPOLI- DM: Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1989) 37(3):233–309.
  • WHITLEY RJ, GNANN JW JR: Acyclovir: a decade later. N Engl. J. Med. (1992) 327(10:782–789.
  • BEUTNER KR: Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res. (1995) 28(4):281–290.
  • PERRY CM, FAULDS D: Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs (1996) 52(5):754–772.
  • BELL AR: Valaciclovir update. Adv. Exp. Med. Biol. (1999) 458:149–157.
  • JARVEST RL, SUTTON D, HODGE RA: Famciclovir. Discovery and development of a novel antiherpesvirus agent. Pharm. Biotechnol (1998) 11:313–343.
  • SACKS SL, WILSON B: Famciclovir/ penciclovir. Adv. Exp. Med. Biol. (1999) 458:135–147.
  • BERG B: Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmac. Ther. (1989) 40:213–285.
  • WAGSTAFF AJ, BRYSON HM: Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs (1994) 48(2):199–226.
  • RABASSEDA X: Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Drugs Today (2003) 39(5):359–371.
  • WHITLEY RJ, ROIZMANN B: Herpes simplex virus infections. Lancet (2001) 357(9267):1513–1518.
  • •An up-to-date review of herpes therapy.
  • KIMBERLIN DW: Neonatal herpes simplex infection. Clin. Microbiol Rev (2004) 17(1):1–13.
  • KIMBERLIN DW, ROUSE DJ: Clinical practice. Genital herpes. N Engl. I Med. (2004) 350(19):1970–1977.
  • KLEYMANN G: Antiviral treatment. In: Herpes Simplex Viruses. M Studahl, P Cinque, T Bergstrom (Eds). Marcel Dekker, Inc., New York, USA (In press).
  • STANBERRY L, CUNNINGHAM A, MERTZ G et al: New developments in the epidemiology, natural history and management of genital herpes. Antiviral Res. (1999) 42(1):1–14.
  • FIELD H, DE CLERCQ E: Antiviral Drugs - a short history of antiviral discovery and development. Microbiology Today (2004) (In press).
  • ROIZMAN B, WHITLEY RJ: The nine ages of herpes simplex virus. Herpes (2001) 8(1):23–27.
  • ANASTASI C, QUELEVER G, BURLET S, GARINO C, SOUARD F, KRAUS JL: New antiviral nucleoside prodrugs await application. Curr. Med. Chem. (2003) 10(18):1825–1843.
  • GORDON YJ: The evolution of antiviral therapy for external ocular viral infections over twenty-five years. Cornea (2000) 19(5):673–680.
  • KAUFMAN HE: Treatment of viral diseases of the cornea and external eye. Frog. Retin. Eye Res. (2000) 19(1):69–85.
  • BARNARD DL: Genvir (Flamel Technologies). Curr. Opin. Investig. Drugs (2001) 2(5):622–623.
  • ALBIN R, CHASER, RISANO C et al: SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2. Antiviral Res. (1997) 35(3):139–146.
  • DANVE-SZATANEK C, AYMARD M, THOU VENOT D et al: Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. I Clin. Microbiol (2004) 42(1):242–249.
  • CHILUKURI S, ROSEN T: Management of acyclovir-resistant herpes simplex virus. Dermatol Clin. (2003) 21(2):311–320.
  • SHIN YK, CAI GY, WEINBERG A, LEARY JJ, LEVIN MJ: Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates. (2001) 39(3):913–917.
  • BACON TH, LEVIN MJ, LEARY JJ, SARISKY RT, SUTTON D: Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. CM'. Microbiol Rev (2003) 16(1):114–128.
  • GILBERT C, BESTMAN-SMITH J, BOIVIN G: Resistance of herpesviruses to drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. (2002) 5(2):88–114.
  • WAXMAN L, DARKEPL: The herpesvirus as targets for antiviral chemotherapy. Anti vir Chem. Chemother. (2000) 11(1):1–22.
  • •Comprehensive review on herpes proteases.
  • JARVEST RL, PINTO IL, ASHMAN SM et al.: Inhibition of herpes proteases and antiviral activity of 2-substituted [2oxazinones. Bioorg. Med.Chem. Lett. (1999) 9(3):443–448.
  • MATSUMOTO M, MISAWA S, CHIBA N, TAKAKU H, HAYASHI H: Selective nonpeptidic inhibitors of herpes simplex virus type 1 and human cytomegalovirus proteases. Biol. Pharm. Bull. (2001) 24(3):236–241.
  • AOKI H, AKAIKE T, ABE K et al: Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virus type 1 in vitro and in vivo. Antimicrob. Agents Chemother. (1995) 39(4):846–849.
  • BJORCK L, GRUBB A, KJELLEN L: Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. Virol (1990) 64(2):941–943.
  • OIEN NL, BRIDEAU RJ, HOPKINS TA et al.: Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob. Agents Chemother. (2002) 46(3):724–30.
  • •A novel compound class with broad-spectrum activity.
  • BRIDEAU RJ, KNECHTEL ML, HUANG A et al.: Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res. (2002) 54(1):19–28.
  • THOMSEN DR, OIEN NL, TA et al.: Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents. J. Virol (2003) 77(3):1868–1876.
  • KUROKAWA M, HOZUMI T, M, KADOTA S, NAMBA T, SHIRAKI K: Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo. I Pharmacol Exp. Ther. (2001) 297(1):372–379.
  • LIUZZI M, DEZIEL R, MOSS N et al.: A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature (1994) 372(6507):695–698.
  • MOSS N, BEAULIEU P, DUCEPPE JS et al.: Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents. Med. Chem. (1995) 38(18):3617–3623.
  • DUAN J, LIUZZI M, PARIS W et al.: Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo. Antimicrob. Agents Chemother. (1998) 42(7):1629–1635.
  • BRIDGES CG, AHMED SP, PS, McCARTHY JR, AS: The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (IVIDL 101,731): a potential topical therapy for herpes simplex virus infection. Antiviral Res. (1995) (4):325–334.
  • SAFRIN S, SCHACKER T, DELEHANTY J, HILL E, COREY L: Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir. Antimicrob. Agents Chemother. (1993) 37(5):975–979.
  • SAFRIN S, SCHACKER T, DELEHANTY J, HILL E, COREY L: Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection. ./. Med. Virol. (1993) (Suppl. 1):146–149.
  • SPECTOR T, HARRINGTON JA, PORTER DJ: Herpes and human ribonucleotide reductases. Inhibition by 2-acetylpyridine 5- [(2-chloroanilino)-thiocarbonyl] -thiocarbonohydrazone (348U87). Biochem. Pharmacol. (1991) 42(1):91–96.
  • SPECTOR T, HARRINGTON JA, MORRISON RW et al.: 2-Acetylpyridine 5- Rdimethylamino)thiocarbonyll - thiocarbonohydrazone (A11 10U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella zoster viruses and a potentiator of acyclovir. Proc. Nati Acad. Sri. USA (1989) 86(3):1051–1055.
  • TURK SR, SHIPMAN C JR, DRACH JC: Selective inhibition of herpes simplex virus ribonucleoside diphosphate reductase by derivatives of 2-acetylpyridine. Biochem. Pharmacol. (1986) 35(9):1539–1545.
  • CARADONNA SJ, CHENG YC: Induction of uracil-DNA glycosylase and dUTP nucleotidohydrolase activity in herpes simplex virus-infected human cells. ./. Biol. Chem. (1981) 256(19):9834–9837.
  • FOCHER F, VERRI A, SPADARI S, MANSERVIGI R, GAMBINO J, WRIGHT GE: Herpes simplex virus type 1 uracil-DNA glycosylase: isolation and selective inhibition by novel uracil derivatives. Biochem. J. (1993) 292(Pt 3):883–889.
  • PYLES RB, THOMPSON RL: Evidence that the herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J. Vim]. (1994) 68(8):4963–4972.
  • SAVVA R, MCAULEY-HECHT K, BROWN T, PEARL L: The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature (1995) 373(6514):487–493.
  • SUN H, ZHI C, WRIGHT GE et al.: Molecular modeling and synthesis of inhibitors of herpes simplex virus type 1 uracil-DNA glycosylase. J. Med. Chem. (1999) 42(13):2344–2350.
  • CHEN R, WANG H, MANSKY LM: Roles of uracil-DNA glycosylase and dUTPase in virus replication. I Gen. Vim]. (2002) 83(Pt 10):2339–2345.
  • WATKINS AM, DUNFORD PJ, MOFFATT AM et al.: Inhibition of virus-encoded thymidine kinase suppresses herpes simplex virus replication in vitro and in vivo. Antivir. Chem. Chemother. (1998) 9(1):9–18.
  • MARTIN JA, THOMAS GJ, JH et al.: The design, synthesis and properties of highly potent and selective inhibitors of herpes simplex virus types 1 and 2 thymidine kinase. Allard]: Chem. Chemother. (1998) 9(1):1–8.
  • MARTIN JA, LAMBERT RW, JH et al.: Nucleoside analogues as highly potent and selective inhibitors of herpes simplex virus thymidine kinase. Bioorg. Med. Chem. Lett. (2001) 11(13):1655–1658.
  • GAUDIO AC, TAKAHATA Y, RICHARDS WG: Prediction of the binding mode of N2-phenylguanine derivative inhibitors to herpes simplex virus 1 thymidine kinase. I Comput. Aided Mol. Des. (1998) 12(1):15–25.
  • XU H, MAGA G, FOCHER F et al.: Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases. J. Med. Chem. (1995) 38(1):49–57.
  • KLEYMANN G, FISCHER R, BETZ UA et al.: New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. (2002) 8(4):392–398.
  • •First tolerable compound class 25 years after the discovery of acyclovir that outperforms the gold standard with respect to all parameters of efficacy in animal models.
  • BETZ UA, FISCHER R, KLEYMANN G, HENDRIX M, RUBSAMEN-WAIGMANN H: Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY-57-1293. Antimicrob. Agents Chemother. (2002) 46(6):1766–1772.
  • KLEYMANN G: Helicase-primase inhibitors. Drugs of the Future (2003) 28(3):257–265.
  • KLEYMANN G: New antiherpes drugs target viral helicase-primase enzymes. Herpes (2003) 10(2):46–52.
  • KLEYMANN G: Discovery and SAR of herpes virus helicase-primase inhibitors. Curt: Med. Chem. (AIA) (2004) 3(1):69–83.
  • KLEYMANN G: Targeting the achilles heel of herpes simplex viruses (HSVs). Antiviral Chemistry Chemotherapy (AVCC) (2004) 15(3):135–140.
  • KLEYMANN G et al.: Preclinical profile of helicase-primase inhibitors. Current Mol. Med. (2005) (Submitted).
  • KLEYMANN G, WERLING HO: A generally applicable, high-throughput screening-compatible assay to identify, evaluate and optimise antimicrobial agents for drug therapy. J. Biomol. Screen. (2004) 9(7):578–587
  • SPECTOR FC, LIANG L, H, SIVARAJA M, PETERSON MG: Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J. Virol. (1998) 72(9):6979–6987.
  • CRUTE JJ, GRYGON CA, KD et al.: Herpes simplex virus helicase-primase inhibitors are active animal models of human disease. Nat. Med. (2002) 8(4):386–391.
  • •Discovery of lead compounds and characterisation of the HSV helicase-primase enzyme complex
  • DUAN J, LIUZZI M, PARIS W et al: Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. Antimicrob. Agents Chemother. (2003) 47(6):1798–804.
  • LIUZZI M, KIBLER P, BOUSQUET C et al.: Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase. Antiviral Res. (2004) 64(3):161–170.
  • CRUMPACKER CS, SCHAFFER PA: New anti-HSV therapeutics target the helicase-primase complex. Nat. Med. (2002) 8(4):327–328.
  • •News and views article on HSV helicase-primase inhibitors.
  • SCHANG LM, BANTLY A, M et al.: Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting, not viral, proteins.Virol (2002)76(15):7874–7882.
  • SCHANG LM: The cell cycle, cyclin-dependent kinases, and viral infections: new horizons and unexpected connections. Frog. Cell Cycle Res. (2003) 5:103–124.
  • LI YH, TAO PZ, LIU YZ, JIANG JD: Geldanamycin, a ligand of heat shock protein 90, inhibits the replication of herpes simplex virus type 1 in vitro. Antimicrob. Agents Chemother. (2004) 48(3):867–872.
  • FITZMAURICE T, HARPER DR, FIELD HJ: Antiviral activity of CTC-8 against herpes simplex virus (HSV-1) in cell culture: evidence for a selective antiviral effect via a cellular mechanism. Antivir. Chem. Chemother. (2003) 14(4):217–223.
  • EBY GA, HALCOMB WW: Use of topical zinc to prevent recurrent herpes simplex infection: review of literature and suggested protocols. Med. Hypotheses (1985) 17(2):157–165.
  • FRANCKE B, MARGOLIN J: Effect of novobiocin and other DNA gyrase inhibitors on virus replication and DNA synthesis in herpes simplex virus type 1-infected BHK cells. J. Gen. Virol (1981) 52(Pt 2):401–404.
  • IKEDA S, YAZAWA M, NISHIMURA C: Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative. Antiviral Res. (1987) 8(3):103–113.
  • WENTLAND MP, PERNI RB, PH et al.: Antiviral properties of 3-quinolinecarboxamides: a series of novel non-nucleoside antiherpetic agents. Drug Des. Discov. (1997) 15(1):25–38.
  • YAMAMOTO N, FURUKAWA H, ITO Y, YOSHIDA S, MAENO K, Y: Anti-herpesvirus activity of citrusinine-I, a new acridone alkaloid, and related compounds. Antiviral Res. (1989) 12(1):21–36.
  • AKANITAPICHAT P, LOWDEN CT, BASTOW KF: 1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. (2000) 45(2):123–134.
  • AKANITAPICHAT P, BASTOW KF: The antiviral agent 5-chloro-1,3-dihydroxyacridone interferes with assembly and maturation of herpes simplex virus. Antiviral Res. (2002) 53(2):113–126.
  • LOWDEN CT, BASTOW KF: Cell culture replication of herpes simplex virus and, or human cytomegalovirus is inhibited by 3,7-dialkoxylated, 1-hydroxyacridone derivatives. Antiviral Res. (2003) 59(3):143–154.
  • EBERT SN, SHTROM SS, MULLER MT: Topoisomerase II cleavage of herpes simplex virus type 1 DNA in vivo is replication dependent. J. Virol (1990) 64(9):4059–4066.
  • YAMADA Y, YAMAMOTO N, K, NISHIYAMA Y: Role of DNA topoisomerase Tin the replication of herpes simplex virus type 2. Arch. Virol (1990) 110(1-2):121–127.
  • PESSINA A, MINEO E, GRIBALDO L, NERI MG: Lack of in vitro antiviral activity of fluoroquinolones against herpes simplex virus type 2. Arch. Virol (1992) 122(3-4):263–269.
  • NOZAWA N, DAIKOKU T, Y et al.: Identification and characterization of the UL7 gene product of herpes simplex virus type 2. Virus Genes. (2002) 24(3):257–266.
  • SAWTELL NM, POON DK, CS, THOMPSON RL: The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with. .1 Vim'. (1998) 72(7):5343–5350.
  • MITCHELL BM, BLOOM DC, COHRS RJ, GILDEN DH, KENNEDY PG: Herpes simplex virus-1 and varicella zoster virus latency in ganglia. J. Neurovirol (2003) 9(2):194–204.
  • THEIL D, HORN AK, DERFUSS T, STRUPP M, ARBUSOW V, BRANDT T: Prevalence and distribution of HSV-1, VZV, and HHV-6 in human cranial nerve nuclei III, IV, VI, VII, and XII. I. Med. Virol (2004) 74(1):102–106.
  • OROZCO-TOPETE R, SIERRA-MADERO J, CANO-DOMINGUEZ C et al.: Safety and efficacy of Virend for topical treatment of genital and anal herpes simplex lesions in patients with AIDS. Antiviral Res. (1997) 35(2):91–103.
  • CHESHENKO N, KELLER MJ, MASCASULLO V et al: Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob. Agents Chemother. (2004) 48(6):2025–2036.
  • GONG Y, MATTHEWS B, CHEUNG D et al.: Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication. Antiviral Res. (2002) 55(2):319–329.
  • TRYBALA E, OLOFSSON S, MARDBERG K et al: Structural and functional features of the polycationic peptide required for inhibition of herpes simplex virus invasion of cells. Antiviral Res. (2004) 62(3):125–134.
  • NYBERG K, EKBLAD M, T et al.: The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus. Antiviral Res. (2004) 63(1):15–24.
  • YASIN B, WANG W, PANG M et al: Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. I Viral. (2004) 78(10):5147–5156.
  • MARCHETTI M, TRYBALA E, SUPERTI F, JOHANSSON M, BERGSTROM T: Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology (2004) 318(1):405–413.
  • BOULWARE SL, BRONSTEIN JC, NORDBY EC, WEBER PC: Identification and characterization of a benzothiophene of herpes simplex virus type 1 replication which acts at the immediate early stage of infection. Antiviral Res. (2001) 51:111–125.
  • VAN ZEIJL M, FAIRHURST J, JONES TR et al.: Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene. J. Virol (2000) 74:9054–9061.
  • NEWCOMB WW, BROWN JC: Inhibition of herpes simplex virus replication by WAY-150138: assembly of capsids depleted of the portal and terminase proteins involved in DNA encapsidation. (2002) 76:10084–10088.
  • NEWCOMB WW, THOMSEN DR, HOMA FL, BROWN JC: Assembly of the herpes simplex virus capsid: identification of soluble scaffold-portal complexes and their role in formation of portal-containing.Virol (2003) 77(18):9862–9871.
  • PILGER BD, CUT C, COEN DM: Identification of a small molecule that inhibits herpes simplex virus DNA Polymerase subunit interactions and viral replication. Chem. Biol. (2004) 11(5):647–654.
  • FONT M, SANMARTIN C, ML et al.: New antiherpetic 1,3-phenylene derivatives, inhibitors of the interaction of the HSV-1 origin binding protein (OBP) with DNA. Drug Des. Discov. (2000) 16(4):295–315.
  • FIRESTINE SM: Recent advances in herpes simplex virus antiviral therapies. Expert Opin. Ther. Patents (2004) 14(8):1139–1151.
  • COMBRINK K: Non-HIV antivirals - a review of the recent patent literature. 'Drugs (2002) 5(8):815–827.
  • CRUMPACKER CS: Use of antiviral drugs to prevent herpesvirus transmission. N Engl. J. Med. (2004) 350(1):67–68.
  • COREY L, WALD A, PATEL R et al: Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce risk of transmission of genital herpes. Engl. J. Med. (2004) 350(1):11–20.
  • HARMENBERG JG, AWAN AR, ALENIUS S et al: ME-609: a treatment for recurrent herpes simplex virus infections. Antivir. Chem. Chemother. (2003) 14(4):205–215.
  • MATTHEWS JT, TERRY BJ, FIELD AK: The structure and function of the HSV DNA replication proteins: defining novel antiviral targets. Antiviral Res. (1993) 20(2):89–114.
  • COEN DM, SCHAFFER PA: Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat. Rev Drug Discovery (2003) 2:278–288.
  • FRICK DN: Helicases as antiviral drug targets. Drug News Perspect. (2003) 16(6):355–362.
  • VISALLI RJ, VAN ZEIJL M: DNA encapsidation as a target for anti-herpesvirus drug therapy. Antiviral Res. (2003) 59(2):73–87.
  • EIZURU Y: Development of new antivirals for herpesviruses. Anti vir Chem. Chemother. (2003) 14(6):299–308.
  • Broccoli compound inhibits HSV. AIDS in patients care STDS.(2003)17(11):609.
  • AVUNDUK AM, VARNELL ED, KAUFMAN HE: The effect of roscovitine on herpetic keratitis. Exp Eye Res. (2003) 76(6):679–683.
  • PETRERA E, JOSELEVICH M, GHINI A, BURTON G, COTO CE: Antiherpes virus activities of new 6-19 carbon-bridged steroids and some synthetic precursors. Anti vir Chem. Chemother. (2003) 14(5):243–248.
  • AL-WAILI NS: Topical honey application versus acyclovir for the treatment of recurrent herpes simplex lesions. Med. Sci. Monit. (2004) 10(8):MT94-MT98.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.